AbbVie Inc. (NYSE:ABBV) to Issue $1.73 Quarterly Dividend

AbbVie Inc. (NYSE:ABBV) declared a quarterly dividend on Thursday, June 18th. Investors of record on Wednesday, July 15th will be given a dividend of 1.73 per share on Friday, August 14th. This represents a c) dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date is Wednesday, July 15th.

AbbVie has raised its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 53 consecutive years. AbbVie has a payout ratio of 49.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect AbbVie to earn $16.30 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 42.5%.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $216.63 on Friday. AbbVie has a 12 month low of $181.73 and a 12 month high of $244.81. The firm has a market capitalization of $382.74 billion, a P/E ratio of 106.71, a P/E/G ratio of 0.68 and a beta of 0.32. The company’s fifty day moving average price is $212.08 and its 200 day moving average price is $218.78.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.46 earnings per share. On average, sell-side analysts anticipate that AbbVie will post 14.3 EPS for the current year.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie declared a quarterly cash dividend of $1.73 per share, reinforcing its shareholder-return profile and highlighting the company’s ability to generate strong cash flow. AbbVie Declares Quarterly Dividend
• Positive Sentiment: AbbVie also got a regulatory boost with new SKINVIVE approval and reported encouraging CLL trial results, which support the company’s oncology and aesthetics growth pipeline. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
• Positive Sentiment: The company presented new Phase 3 data on a venetoclax-based combination and highlighted its late-stage ABBV-400 colorectal cancer program, adding to investor confidence in AbbVie’s long-term pipeline. AbbVie Inc. (ABBV) Presents Data on Fixed-Duration Venetoclax-Based Combination
• Neutral Sentiment: AbbVie has been attracting extra trader attention recently, but the stock’s near-term direction still depends on whether dividend income and pipeline progress can outweigh broader market weakness and legal uncertainty. AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: The biggest overhang is a reported HHS move to ask a court to dismiss AbbVie’s lawsuit over drug-discount patients, which could increase regulatory and legal pressure on the stock. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.